Table: Anges - 9-MTH group results
Oct 26 (Reuters)-
Anges, Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2020 Sep 30, 2019 Dec 31, 2020
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 28 mln 323 mln
(-91.2 pct) (+17.2 pct)
Operating loss 2.86 loss 2.36
Recurring loss 3.15 loss 2.39
Net loss 3.17 loss 2.77
EPS loss 27.08 yen loss 26.65 yen
Ann Div NIL NIL
-Q2 div NIL NIL
-Q4 div NIL NIL
NOTE - Anges, Inc..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4563.T
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001